Abstract
In cancer cells, hypoxia can lead to resistance to both radiation and chemotherapy. The ability to measure cellular hypoxia is an useful tool in therapeutic planning. [18F]Fluoromisonidazole ([18F]FMISO) is a specific tracer used for the detection of hypoxic tissues by positron emission tomography (PET). In this research, the [18F]FMISO radiosynthesis has been modified to reduce costs to support clinical studies of patients with hypoxia by using an automated module instead of the disposable cassette-based synthesizer. The Synthra RNplus module, a remote-controlled synthesizer, was used for nucleophilic substitution of NITTP (1-(2'-nitro-1'-imidazolyl)-2-O-tetrahydropyranyl-3-O-toluenesulfonyl-propanediol) with [18F]fluoride anion. Labeling of the 5 mg of NITTP precursor in anhydrous dimethyl sulfoxide (DMSO) was performed at 100 ℃ for 10 min and hydrolyzed with 1 M hydrochloric acid (HCl) at 100 ℃ for 5 min. Finally, the purified product was obtained by using solid phase extraction (SPE) cartridge instead of high-performance liquid chromatography (HPLC). The total [18F]FMISO yield was approximately 29.11 ± 5.00 % (n = 7), the total synthesis time was less than 35 min, and the radiochemical purity was greater than 95 %. These results are very useful for supporting hypoxia diagnosis in cancer patients in Thailand.
 HIGHLIGHTS
 
 Rapid and simplified [18F]FMISO radiosynthesis are very useful for supporting hypoxia diagnosis in cancer patients in Thailand
 [18F]FMISO radiosynthesis using Synthra RNplus with SPE purification takes less than 35 min
 [18F]FMISO yield is approximately 29.11 ± 5.00 % (n = 7, non-decay corrected) and the radiochemical purity is greater than 95 %
 
 GRAPHICAL ABSTRACT
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
